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background: Traditionally it has been presumed that patients with significant left ventricular dysfunction will also have low trans-aortic flow. 
Recognizing that it is possible to have a normal trans-aortic flow despite significant left ventricular dysfunction, indexed stroke volume (SVi) 
has been used to characterize flow state in aortic stenosis. However, little is known about the impact of pre-procedural SVi on the long-term 
outcome of patients following transcatheter aortic valve implantation (TAVI). We aimed to evaluate the impact of SVi on 3-year all-cause 
mortality of patients with severe aortic stenosis following TAVI.
methods: Patients with severe and symptomatic aortic stenosis (effective orifice area [EOA]≤1cm²) who were scheduled for TAVI with 
Corevalve at our institution were prospectively enrolled. Prospectively collected clinical and echocardiographic data were retrospectively 
analyzed in all patients. Primary clinical end-point was all cause mortality defined according to the criteria proposed by the Valve Academic 
Research Consortium.
results: We included 137 patients (mean age: 79.8±7.0 years). Ninety-nine (72.3%) patients had normal flow (SVi≥35ml/m2) and 38 
(27.7%) low flow (SVi<35ml/m2). The primary clinical end point occurred in 27 patients (19.7%) during a median follow-up period of 
3 years. Mean pre-procedural SVi was lower in patients that reached the primary end-point (39.3±8.3 ml/m2 versus 46.9±16.3ml/m2, 
p=0.01). Patients with low flow had higher 3-year all cause mortality compared with those in the normal flow group (36.8% versus 13.1%, 
p<0.01). An inverse relationship was observed between SVi and mortality, with a 5% increase in mortality per every 1 ml/m2 decrease in 
SVi (p=0.02, OR: 0.95, 95% CI:0.92-0.99).
Conclusion:  Lower SVi is incrementally associated with increased mortality and an independent predictor of outcome in patients with 
severe aortic stenosis following TAVI. Based on these findings, SVi should be included in the risk stratification of these patients.
